drugset
Drugs / rVSV∆G-LASV-GPC
last change Nov 2025 re-read 3 minutes ago

rVSV∆G-LASV-GPC

also known as rVSVΔG-LASV-GPC

Vaccine

Developed for
Lassa fever
Investigated by
International AIDS Vaccine Initiative · Brigham and Women's Hospital · Coalition for Epidemic Preparedness Innovations · East-West Medical Research Institute · George Washington University · Redemption Hospital

Trials 2

today NCT05868733 · Ph 2 NCT04794218 · Ph 1
202220232024202520262027
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 11 trial
Phase 1 NCT04794218 Jun 2021 → Dec 2023 Lassa fever International AIDS Vaccine Initiative Unknown No outcome recorded
Phase 21 trial
Phase 2 NCT05868733 Mar 2024 → Dec 2026 expected Lassa fever International AIDS Vaccine Initiative Recruiting No outcome recorded

Evidence & citations 4 cited values

Every value below carries the sentence it was read from. 3 sources stand behind the page.

FieldValueCited text
Known as rVSV∆G-LASV-GPC “A Phase 2 Randomized, Double-Blinded, Placebo-Controlled Clinical Trial to Evaluate the Safety, Tolerability, and Immunogenicity of rVSV∆G-LASV-GPC Vaccine in Adults and...” NCT05868733 ↗
1

NCT04794218 ↗
Known as rVSVΔG-LASV-GPC “A replication-competent recombinant vesicular stomatitis virus-vectored vaccine encoding a Lassa virus (LASV) glycoprotein complex, rVSVΔG-LASV-GPC, has been developed, but...” PMID 41191941 ↗ Nov 2025
Modality Vaccine “A replication-competent recombinant vesicular stomatitis virus-vectored vaccine encoding a Lassa virus (LASV) glycoprotein complex” PMID 41191941 ↗ Nov 2025
Route Intramuscular “we randomly assigned healthy adults (18 to 50 years of age) to receive rVSVΔG-LASV-GPC or placebo intramuscularly” PMID 41191941 ↗ Nov 2025